MICSI vs Manus AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
US MRI microstructure imaging algorithm (FDA-cleared July 2024) adding higher resolution to existing scanners projecting $2M additional annual revenue per scanner; YC $1.49M competing with Subtle Medical and Siemens AI-Rad Companion for radiology AI.
About
MICSI is a United States-based medical imaging technology company — backed by Y Combinator with $1.49 million raised from Graphene Ventures, NVO Capital, NYU Entrepreneurial Institute, Orange Collective, and Pioneer Fund — providing hospitals, radiology centers, and healthcare providers with the MICSI-RMT software (FDA-cleared July 2024), a Microstructure Imaging algorithm that analyzes standard MRI scanner data to generate higher-resolution tissue microstructure images and enable faster scan protocols, projecting $2 million in additional annual revenue per MRI scanner deployment for healthcare customers through improved diagnostic throughput and imaging quality. MICSI's technology works as a software overlay on existing MRI hardware — requiring no capital equipment purchase — making it deployable across the 35,000+ installed clinical MRI scanners in the United States.
General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.
About
Manus AI is a general-purpose autonomous AI agent developed by Butterfly Effect Pte Ltd, founded in 2022 by Yichao "Peak" Ji and Xiao Hong. Relocated from China to Singapore (mid-2025). Launched March 6, 2025, autonomously handling complex tasks like market research, coding, data analysis, and content creation without human intervention.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.